Skip to main content

Microbial-Based Cancer Therapy

Edited by Neil S. Forbes and Grant McFadden

While microbial based therapy is one of the oldest cancer therapy modalities, dating from the 1880s, the field is not well-developed. Even after all this time, the cancer therapeutics potential of microbes has not been well-studied and has not materialized into treatments. This journal collection comes at a time in which new research tools and better knowledge of tumor biology and microbial virulence are available to lend new perspectives.

This collection describes the complex nature of the microbe-tumor interaction and discusses recent advances in the field that take advantage of the unique ability of microbes to invade human cells and induce immune responses in order to create therapeutic approaches that direct microbes to selectively target tumors. Including sections on microbe-tumor interactions, virus and bacteria-based therapies, this series also highlights opportunities for microbial based therapy where conventional therapy is inadequate.  

We hope that these papers will stimulate more research interest in the field and unleash new tools based on microbial virulence against cancer.

  1. In this White Paper, we discuss the current state of microbial cancer therapy. This paper resulted from a meeting (‘Microbial Based Cancer Therapy’) at the US National Cancer Institute in the summer of 2017. H...

    Authors: Neil S. Forbes, Robert S. Coffin, Liang Deng, Laura Evgin, Steve Fiering, Matthew Giacalone, Claudia Gravekamp, James L. Gulley, Hal Gunn, Robert M. Hoffman, Balveen Kaur, Ke Liu, Herbert Kim Lyerly, Ariel E. Marciscano, Eddie Moradian, Sheryl Ruppel…
    Citation: Journal for ImmunoTherapy of Cancer 2018 6:78
  2. Antiviral responses are barriers that must be overcome for efficacy of oncolytic virotherapy. In mammalian cells, antiviral responses involve the interferon pathway, a protein-signaling cascade that alerts the...

    Authors: Donald Bastin, Amelia S. Aitken, Adrian Pelin, Larissa A. Pikor, Mathieu J. F. Crupi, Michael S. Huh, Marie-Claude Bourgeois-Daigneault, John C. Bell and Carolina S. Ilkow
    Citation: Journal for ImmunoTherapy of Cancer 2018 6:62
  3. Oncolytic viruses are currently experiencing accelerated development in several laboratories worldwide, with some forty-seven clinical trials currently recruiting. Many oncolytic viruses combine targeted cytot...

    Authors: Janet Lei, Egon J. Jacobus, William K. Taverner, Kerry D. Fisher, Silvio Hemmi, Katy West, Lorna Slater, Fred Lilley, Alice Brown, Brian Champion, Margaret R. Duffy and Len W. Seymour
    Citation: Journal for ImmunoTherapy of Cancer 2018 6:55
  4. Talimogene Laherparepvec (T-VEC) is an oncolytic virus approved as an intratumoral therapy for treating unresectable stage IIIB-IV metastatic melanoma. The mechanisms of action for T-VEC and checkpoint inhibit...

    Authors: Lillian Sun, Pauline Funchain, Jung Min Song, Patricia Rayman, Charles Tannenbaum, Jennifer Ko, Michael Mcnamara, C. Marcela Diaz-Montero and Brian Gastman
    Citation: Journal for ImmunoTherapy of Cancer 2018 6:36